Cargando…
Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer
Resistance to targeted drugs is now a challenging clinical problem in the treatment of non-small cell lung cancer (NSCLC). So far, there are no approved targeted therapeutic drugs for patients with disease progression after the third-generation epidermal growth factor receptor-tyrosine kinase inhibi...
Autores principales: | Li, Hang, Muhetaer, Gulizeba, Xie, Yizi, Yao, Kainan, Ma, Qianqian, Guan, Huiting, Xing, Sizhong, Huang, Xiufang, Zhou, Jihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719927/ https://www.ncbi.nlm.nih.gov/pubmed/36479196 http://dx.doi.org/10.3389/fphar.2022.1071365 |
Ejemplares similares
-
Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor
por: Aliko, Ardita, et al.
Publicado: (2019) -
Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer
por: Beato, Miguel, et al.
Publicado: (2020) -
Peptidyl Arginine Deiminase Type 4 Gene Promoter Hypo-Methylation in Rheumatoid Arthritis
por: Kolarz, Bogdan, et al.
Publicado: (2020) -
Implications of Porphyromonas gingivalis peptidyl arginine deiminase and gingipain R in human health and diseases
por: Chow, Yoke Chan, et al.
Publicado: (2022) -
Expression of Peptidyl Arginine Deiminase 2 Is Closely Associated with Recurrence in Patients with Hepatocellular Carcinoma
por: Uhm, Sunho, et al.
Publicado: (2023)